Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MULTIPLE-CENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 PART 2 A RANDOMIZED, SINGLE DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION

Next Previous
X
Search
Trial Profile

A MULTIPLE-CENTER, OPEN-LABEL CLINICAL PHARMACOLOGY STUDY WITH RO5503781, AN MDM2 ANTAGONIST, IN PATIENTS WITH SOLID TUMORS TO DETERMINE: PART 1 ONE-SEQUENCE, 2-PERIOD CROSSOVER DESIGN TO INVESTIGATE THE EFFECT OF POSACONAZOLE, A STRONG CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF RO5503781 PART 2 A RANDOMIZED, SINGLE DOSE, 3 PERIOD CROSSOVER DESIGN TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF TWO NEW RO5503781 TABLET FORMULATIONS FOLLOWING ORAL ADMINISTRATION

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idasanutlin (Primary) ; Posaconazole
  • Indications Lymphoma; Solid tumours
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Roche

    • Most Recent Events

    • 11 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 23 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 05 Feb 2015 Planned number of patients changed from 30 to 50, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top